• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday

    10/3/23 10:09:34 AM ET
    $CLNE
    $FVRR
    $LLY
    $LNTH
    Natural Gas Distribution
    Utilities
    Real Estate
    Real Estate
    Get the next $CLNE alert in real time by email

    U.S. stocks traded lower, with the Nasdaq Composite falling more than 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

    Vericity, Inc. (NASDAQ:VERY) shares climbed 87% to $11.11 after iA Financial Group announced it will acquire the company.

    POINT Biopharma Global Inc. (NASDAQ:PNT) gained 84% to $12.30. Eli Lilly And Co (NYSE:LLY) agreed to acquire POINT Biopharma Global at $12.50 per share in cash, an aggregate of approximately $1.4 billion.

    Clean Energy Fuels Corp. (NASDAQ:CLNE) rose 10.5% to $3.9691. Raymond James upgraded Clean Energy Fuels from Outperform to Strong Buy and announced a $6 price target.

    Warby Parker Inc. (NYSE:WRBY) gained 9% to $14.47. Evercore ISI Group upgraded Warby Parker from In-Line to Outperform and announced a $20 price target.

    Lantheus Holdings, Inc. (NASDAQ:LNTH) climbed 7% to $72.34 possibly after Eli Lilly agreed to acquire POINT Biopharma. Lantheus and POINT are partners for certain cancer programs.

    Oddity Tech Ltd. (NASDAQ:ODD) gained 6.1% to $29.79 after the company reported solid preliminary third-quarter results, allowing it to deliver net revenue growth of at least 58% in the first three quarters of 2023.

    Fiverr International Ltd. (NYSE:FVRR) rose 6% to $25.50. Roth MKM upgraded Fiverr Intl from Neutral to Buy and announced a $33 price target.

    Studio City International Holdings Limited (NYSE:MSC) climbed 5.4% to $5.81.

    NuScale Power Corporation (NYSE:SMR) gained 4.7% to $4.72.

    Synaptics Incorporated (NASDAQ:SYNA) climbed 4% to $91.51. Keybanc maintained Synaptics with an Overweight and raised the price target from $100 to $115.

    Now Read This: Top 4 Defensive Stocks That Could Lead To Your Biggest Gains In October

    Get the next $CLNE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNE
    $FVRR
    $LLY
    $LNTH

    CompanyDatePrice TargetRatingAnalyst
    Fiverr International Ltd.
    $FVRR
    3/2/2026Buy → Neutral
    BTIG Research
    NuScale Power Corporation
    $SMR
    2/27/2026$21.00Market Perform → Outperform
    Northland Capital
    Lantheus Holdings Inc.
    $LNTH
    2/26/2026Mkt Perform → Outperform
    William Blair
    ODDITY Tech Ltd.
    $ODD
    2/26/2026$23.00Outperform → In-line
    Evercore ISI
    ODDITY Tech Ltd.
    $ODD
    2/26/2026$16.00Overweight → Neutral
    Analyst
    ODDITY Tech Ltd.
    $ODD
    2/26/2026$13.00Equal Weight → Underweight
    Barclays
    ODDITY Tech Ltd.
    $ODD
    2/26/2026$10.00Buy → Underperform
    BofA Securities
    ODDITY Tech Ltd.
    $ODD
    2/25/2026Buy → Hold
    Needham
    More analyst ratings

    $CLNE
    $FVRR
    $LLY
    $LNTH
    SEC Filings

    View All

    SEC Form S-8 filed by Fiverr International Ltd.

    S-8 - Fiverr International Ltd. (0001762301) (Filer)

    3/12/26 4:14:31 PM ET
    $FVRR
    Real Estate

    SEC Form S-8 filed by Fiverr International Ltd.

    S-8 - Fiverr International Ltd. (0001762301) (Filer)

    3/12/26 4:12:43 PM ET
    $FVRR
    Real Estate

    SEC Form 20-F filed by Fiverr International Ltd.

    20-F - Fiverr International Ltd. (0001762301) (Filer)

    3/12/26 4:06:37 PM ET
    $FVRR
    Real Estate

    $CLNE
    $FVRR
    $LLY
    $LNTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Niedzwiecki Daniel was granted 36,692 shares and covered exercise/tax liability with 1,283 shares, increasing direct ownership by 42% to 119,376 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/9/26 5:06:05 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Officer Dinkelborg Ludger was granted 20,966 shares, increasing direct ownership by 142% to 35,731 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/9/26 5:05:49 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CFO and Treasurer Marshall Robert J. Jr. was granted 38,002 shares and covered exercise/tax liability with 1,182 shares, increasing direct ownership by 43% to 122,792 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    3/9/26 5:05:33 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fiverr Files its Annual Report on Form 20-F

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Fiverr International Ltd. (NYSE:FVRR), the company that is transforming the way the world creates and works together, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the Securities and Exchange Commission on March 12, 2026. The annual report on Form 20-F can be accessed on the Company's investor relations website at http://investors.fiverr.com or on the SEC's website at www.sec.gov. Fiverr will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed in writing by

    3/12/26 5:00:00 PM ET
    $FVRR
    Real Estate

    ODDITY Tech Announces $200m Share Buyback Plan

    NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. ("ODDITY") (NASDAQ:ODD), today announced that its Board of Directors has approved a share buyback program (the "Buyback Plan") authorizing the repurchase of a maximum of $200 million of the Company's Class A ordinary shares, subject to market conditions, legal and regulatory constraints, the terms of the Buyback Plan, and other strategic priorities. The Buyback Plan replaces and supersedes the Company's previously announced $150 million share buyback plan. The Buyback Plan will expire on March 31, 2029 or once the allocated funds have been fully deployed, subject to any future modifications by the Board. Oddity had repurchased

    3/12/26 8:00:00 AM ET
    $ODD
    Package Goods/Cosmetics
    Consumer Discretionary

    Framatome and NuScale Power Contract to Support Global Supply Chain and Accelerate Fuel Delivery

    Framatome and NuScale Power Corporation (NYSE:SMR) have expanded their longstanding partnership to include Framatome's European facilities for fuel fabrication in Europe, while also notifying the Richland facility to fabricate fuel for NuScale Power's U.S. Nuclear Regulatory Commission (NRC)-approved SMR fuel technology in the next five years. This expansion leverages Framatome's global presence to support NuScale in meeting global U.S. and European demands and builds upon their exclusive fuel manufacturing contract signed in 2015. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310799415/en/ Framatome's European facilities wi

    3/10/26 4:15:00 PM ET
    $SMR
    Metal Fabrications
    Industrials

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fiverr downgraded by BTIG Research

    BTIG Research downgraded Fiverr from Buy to Neutral

    3/2/26 8:54:59 AM ET
    $FVRR
    Real Estate

    NuScale Power upgraded by Northland Capital with a new price target

    Northland Capital upgraded NuScale Power from Market Perform to Outperform and set a new price target of $21.00

    2/27/26 8:22:27 AM ET
    $SMR
    Metal Fabrications
    Industrials

    Lantheus Holdings upgraded by William Blair

    William Blair upgraded Lantheus Holdings from Mkt Perform to Outperform

    2/26/26 12:20:43 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NuScale Power Corporation

    SC 13D/A - NUSCALE POWER Corp (0001822966) (Subject)

    11/27/24 7:35:05 AM ET
    $SMR
    Metal Fabrications
    Industrials

    Amendment: SEC Form SC 13G/A filed by ODDITY Tech Ltd.

    SC 13G/A - Oddity Tech Ltd (0001907085) (Subject)

    11/18/24 9:49:27 PM ET
    $ODD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Financials

    Live finance-specific insights

    View All

    NuScale Power Reports Fourth Quarter and Full Year 2025 Results

    NuScale's exclusive global strategic partner, ENTRA1 Energy ("ENTRA1"), and Tennessee Valley Authority ("TVA") continue to advance the largest nuclear power deployment program in U.S. history NuScale completes work on Fluor's Phase 2 Front-End Engineering and Design ("FEED") study for the RoPower Doicești, Romania power plant Study shows NuScale Power technology can support profitable, reliable power for chemical plants, validating exciting NuScale use case NuScale further strengthens cash position through capital market activities NuScale Power Corporation (NYSE:SMR) ("NuScale", "NuScale Power" or the "Company"), the industry-leading provider of proprietary and innovative a

    2/26/26 4:15:00 PM ET
    $SMR
    Metal Fabrications
    Industrials

    Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growthCompany provides full year 2026 rev

    2/26/26 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Warby Parker Announces Fourth Quarter and Full Year 2025 Results

    Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2025. Highlights Delivered revenue growth of 13.0% for full year 2025 and 11.2% for the fourth quarter. Drove Active Customer growth of 7.0%, and Average Revenue per Customer of $324, up 5.7% year over year. Achieved first full year of positive net income of $1.6 million, and expanded Adjusted EBITDA(1) by 30.2% year over year to $95.2 million and Adjusted EBITDA Margin(1) by 140 basis points to 10.9%. Delivered third consecutive year of positive operating cash

    2/26/26 6:45:00 AM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    $CLNE
    $FVRR
    $LLY
    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Warby Parker Appoints Adrian Mitchell as Chief Financial Officer

    Warby Parker Inc. (NYSE:WRBY), a direct-to-consumer lifestyle brand focused on vision for all, today announced the appointment of Adrian Mitchell as Chief Financial Officer, effective February 10, 2026. His appointment strengthens Warby Parker's leadership team as the company continues executing its strategic vision, building on a track record of retail and product innovation while expanding into new categories, including the launch of its first AI glasses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209259218/en/Adrian Mitchell, Chief Financial Officer Mitchell has more than 25 years of experience leading some of the worl

    2/9/26 4:10:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Synaptics Appoints Venkatesh (Venk) Nathamuni to Board of Directors

    SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Synaptics® Incorporated (NASDAQ:SYNA) ("Company") today announced that on December 29, 2025, its Board of Directors ("Board") appointed Venkatesh (Venk) Nathamuni to serve as a member of the Company's Board and as a member of its Audit Committee, with service commencing on January 1, 2026. Mr. Nathamuni has more than 30 years of leadership experience with deep expertise in corporate finance, strategy, mergers and acquisitions, investor relations, and public company governance. He has held senior executive positions at Cirrus Logic, Inc., Arista Networks, Inc., and Maxim Integrated Products, Inc., and earlier in his career served as a semi

    1/5/26 8:55:00 AM ET
    $SYNA
    Semiconductors
    Technology